SATSUMA PHARMACEUTICALS, INC. (STSA): Price and Financial Metrics


SATSUMA PHARMACEUTICALS, INC. (STSA): $0.94

-0.01 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add STSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

STSA Stock Price Chart Interactive Chart >

Price chart for STSA

STSA Price/Volume Stats

Current price $0.94 52-week high $8.08
Prev. close $0.95 52-week low $0.59
Day low $0.93 Volume 167,671
Day high $0.98 Avg. volume 142,159
50-day MA $0.89 Dividend yield N/A
200-day MA $3.74 Market Cap 30.98M

SATSUMA PHARMACEUTICALS, INC. (STSA) Company Bio


Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.


STSA Latest News Stream


Event/Time News Detail
Loading, please wait...

STSA Latest Social Stream


Loading social stream, please wait...

View Full STSA Social Stream

Latest STSA News From Around the Web

Below are the latest news stories about SATSUMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate STSA as an investment opportunity.

Despite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For Approval

Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) provided an update on its STS101 development program and corporate update. Further analysis of results from the recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating and sustained antimigraine effects on clinically critical secondary endpoints. Satsuma believes the results … Full story available on Benzinga.com

Benzinga | December 20, 2022

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpointsQualitative and quantitative primary market research conducted post-SUMMIT trial readout and incorporating updated STS101 profile consistent with SUMMIT trial results indicates headache specialists continue to have strong interest in STS101, with high prescribers o

Yahoo | December 20, 2022

Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) Shares Surged 7.79% In A Week – But Can It Maintain Its Gains?

In last trading session, Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) saw 0.57 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.94 trading at $0.16 or 19.87% at ring of the bell on the day assigns it a market valuation of $30.73M. That closing price of STSA’s stock is … Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) Shares Surged 7.79% In A Week – But Can It Maintain Its Gains? Read More »

Marketing Sentinel | December 17, 2022

As Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) gains 14%, insiders who bought last year may be wishing they had bet higher

Insiders who bought Satsuma Pharmaceuticals, Inc. ( NASDAQ:STSA ) stock in the last 12 months were richly rewarded last...

Yahoo | November 30, 2022

Volume Buzzers: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), Asensus Surgical, Inc. (AMEX:ASXC)

Satsuma Pharmaceuticals, Inc. (STSA) with the stream of 1.77 also noticed, India Asensus Surgical, Inc. (ASXC) encountered a rapid change of 0.95 in the last hour of Monday’s trading session. … The post Volume Buzzers: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), Asensus Surgical, Inc. (AMEX:ASXC) appeared first on Stocks Equity .

Stock Equity | November 28, 2022

Read More 'STSA' Stories Here

STSA Price Returns

1-mo 4.44%
3-mo -80.89%
6-mo -80.50%
1-year -82.10%
3-year -96.20%
5-year N/A
YTD 4.44%
2022 -80.00%
2021 -2.39%
2020 -76.58%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5782 seconds.